Anzeige
Erschienen in:
02.08.2021 | Original Article
Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma
Erschienen in: Hepatology International | Ausgabe 5/2021
Einloggen, um Zugang zu erhaltenAbstract
Background and purpose
Radiofrequency ablation (RFA) is the standard of care for early stage hepatocellular carcinoma (HCC). However, the clinical outcomes of iodized oil computed tomography (IoCT) versus ultrasound (US)-guided RFA for HCC remain unclear.
Methods
We retrospectively analyzed consecutive treatment-naïve patients who received curative RFA for HCC within Milan criteria from January 2016 to December 2018. Patients who underwent either IoCT-guided RFA (IoCT group) or US-guided RFA (US group) were included. Various clinical factors, including tumor location, were adjusted with a 1:1 propensity score matching. Subsequently, the cumulative incidence rates for recurrence and hazard ratios for survival were calculated.
Results
We included 184 (37.9%) and 301 (62.1%) patients who received IoCT- and US-guided RFA, respectively. Before propensity score matching, IoCT guidance was significantly associated with multiple tumors, higher body mass index, lower albumin level, and tumors located at S8. After matching, the 1-, 2-, and 3-year local tumor progression rates of the IoCT group were significantly lower than those of the US group (4.4%, 6.9%, and 7.5% vs. 14.4%, 16.3%, and 16.3%, respectively, at p = 0.002, 0.009, and 0.016, respectively). In univariate analyses and multivariate analyses that adjusted for clinical and tumor location-related parameters, the IoCT group had better recurrence-free survival (hazard ratio = 0.581, 95% confidence interval 0.375–0.899) than those with US guidance but not overall survival.
Conclusion
IoCT-guided RFA had a lower local tumor progression rate and better recurrence-free survival than did US-guided RFA for HCC within the Milan criteria.
Graphic abstract
-
CT-guide RFA is a safe and effective alternative to US-guided with similar overall survival.
-
IoCT-guided RFA might have a better local tumor control than US-guided.
-
IoCT-guided RFA may be more suitable for male patients, aged < 70 years, a single tumor measuring 2–5 cm, and a tumor located at the subdiaphragmatic/subcardiac region.
×
![]()